Chiral Quest (Suzhou) Co., Ltd. is a leading provider of world-class asymmetric hydrogenation technology. Our unique catalysts offer significant advantages in both research and development and manufacturing. We are dedicated to the development and production of safe, cost-effective, and high-quality intermediates for the pharmaceutical industry. Our services include customized research and production for intermediates, RSMs, and GMP intermediates, catering to global pharmaceutical companies.

In 2012, Chiral Quest (Suzhou) Co., Ltd. merged with Jiangxi LongLife Bio-pharmaceutical Co., Ltd., and in 2020, with Suzhou Pengxu PharmaTech Co., Ltd. Additionally, in 2019, Suzhou LongLife Bio-Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Suzhou Pengxu, was established. Chiral Quest serves as the parent company of the group, with Jiangxi LongLife as the manufacturing site and Suzhou LongLife as the research and development center. Furthermore, we have offices located in the United States and the United Kingdom.

With over 600 employees, including nearly 150 individuals in our R&D center, all of whom hold at least a bachelor's degree, Chiral Quest (Suzhou) Co., Ltd. possesses a highly qualified and skilled workforce. Our core R&D team consists of 30+ professionals with master degrees and 9 professionals with Ph.D. degrees. 

At Chiral Quest, we embrace the values of integrity, responsibility, execution, teamwork, innovation, and communication. Our goal is to deliver cutting-edge technology, exceptional services, and top-quality products to our global customers.​

Integrity, responsibility, execution, teamwork, innovation, and communication